Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is highlighted as one of the best affordable growth stocks to buy, with Cory Kasimov maintaining a Buy rating and setting a price target of $750 on August 27.

On August 26, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported positive results for its Cemdisiran monotherapy in Myasthenia Gravis Activities of Daily Living total score, leading to plans for a US regulatory submission in Q1 2026.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) focuses on developing therapies for diseases like cancer and eye disorders, with around 40 programs in progress. Key products driving growth include Dupixent for eczema and Eylea for wet age-related macular degeneration.

Despite the potential of REGN, investors are advised to consider other AI stocks with greater upside potential and lower downside risk. A free report on the best short-term AI stock is recommended for those seeking undervalued investments.

For more stock insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. No disclosures were made in this article.

Read more at Yahoo Finance: Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT